Barclays initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Overweight rating and a price target of $38.00.Analyst Gena Wang ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE